These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 570995)

  • 1. The influence of endogenous serum C1q on the 125I-C1q binding test.
    Soltis RD; Morris MJ; Hasz DE; Wilson ID
    J Lab Clin Med; 1979 Feb; 93(2):238-45. PubMed ID: 570995
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of heat inactivation of serum on the detection of immune complexes.
    Soltis RD; Hasz D; Morris MJ; Wilson ID
    J Clin Lab Immunol; 1979 Feb; 1(4):321-7. PubMed ID: 91683
    [No Abstract]   [Full Text] [Related]  

  • 3. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
    Pearlstein E; Sorvillo J; Gigli I
    J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 125I-C1q binding activity of soluble antigen-antibody complexes formed in vitro.
    Soltis RD; Hasz DE
    J Clin Lab Immunol; 1982 Nov; 9(2):121-31. PubMed ID: 6984078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.
    Wu CC; Bey RF; Loken KI
    Am J Vet Res; 1988 Jun; 49(6):865-9. PubMed ID: 3135770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.
    Zubler RH; Lange G; Lambert PH; Miescher PA
    J Immunol; 1976 Jan; 116(1):232-5. PubMed ID: 1245740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of the fluid phase C1q binding assay. The effect of endogenous C1q on the precipitation and detection of an immune complex model.
    Jacobs RJ; Mocharla R
    J Immunol Methods; 1988 May; 109(2):265-75. PubMed ID: 3258897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A method of isolating C1q from human serum and its use in the solid-phase immunoenzyme determination of immune complexes].
    Belozerov AP
    Lab Delo; 1989; (3):24-6. PubMed ID: 2469833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.
    Heinz HP; Burger R; Golan MD; Loos M
    J Immunol; 1984 Feb; 132(2):804-8. PubMed ID: 6606678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocyte-derived complement inhibitor. IV. The functional properties of C1 bound to erythrocytes pretreated with leukocyte culture supernatant.
    Bernard A; Walter W; Teshima H; Boumsell L; Good RA; Day NK
    J Immunol; 1976 Oct; 117(4):1117-26. PubMed ID: 977945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first component of complement from the bullfrog, Rana catesbeiana: functional properties of C1- and isolation of subcomponent C1q.
    Alexander RJ; Steiner LA
    J Immunol; 1980 Mar; 124(3):1418-25. PubMed ID: 6965693
    [No Abstract]   [Full Text] [Related]  

  • 12. C1q binding and C1 activation by various isolated cellular membranes.
    Storrs SB; Kolb WP; Olson MS
    J Immunol; 1983 Jul; 131(1):416-22. PubMed ID: 6602834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Binding and activation of the first component of human complement on artificial matrices].
    Kozlov LV; Sizoĭ MN; Zinchenko AA; Ivanov AE; Zubov VP
    Bioorg Khim; 1984 Dec; 10(12):1629-38. PubMed ID: 6529444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between the binding ability and the rate of activation of the complement component C1.
    Folkerd EJ; Gardner B; Hughes-Jones NC
    Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo degradation of rat C1q induced by intravenous injection of soluble IgG aggregates.
    Veerhuis R; van Es LA; Daha MR
    Immunology; 1985 Apr; 54(4):801-10. PubMed ID: 3872261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C1q-binding substances in peripheral lymph in bronchial carcinoma.
    Heier HE; Sokolowski JA; Solheim OP
    Lymphology; 1978 Dec; 11(4):170-3. PubMed ID: 739789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of complexes composed of C1r, C1s, and C1 inactivator in human serum on activation of C1.
    Laurell AB; Johnson U; Mårtensson U; Sjöholm AG
    Acta Pathol Microbiol Scand C; 1978 Dec; 86C(6):299-306. PubMed ID: 153082
    [No Abstract]   [Full Text] [Related]  

  • 18. Complement activation in seropositive and seronegative rheumatoid arthritis. 125I-C1q binding capacity and complement breakdown products in serum and synovial fluid.
    Lambert PH; Nydegger UE; Perrin LH; McCormic J; Fehr K; Miescher PA
    Rheumatology; 1975; 6():52-9. PubMed ID: 1202608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
    Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
    J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first complement component: evidence for an equilibrium between C1s free in serum and C1s bound in the C1 complex.
    Bartholomew RM; Esser AF
    J Immunol; 1977 Dec; 119(6):1916-22. PubMed ID: 915287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.